The HMG-CoA reductase pathway, statins and angioprevention

Seminars in Ophthalmology

Volumn 21, Issue 1, 2006, Pages 29-35

  Feng, Chong ^a,b   Han, Anjia ^b   Ye, Caisheng ^a   Xu, Rui ^b   Li, Mengfeng ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Angiogenesis inhibitors; Chemoprevention

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ATORVASTATIN; EPIGALLOCATECHIN GALLATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SIMVASTATIN;

ANGIOGENESIS; CANCER; CLINICAL TRIAL; ENDOTHELIUM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; ANIMAL; DRUG EFFECT; ENZYMOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33646945885     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530500509382     Document Type: Review

References (48)

1. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D.Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284:808-12.
2. Bisacchi D, Benelli R, Vanzetto C, Ferrari N, Tosetti F, Albini A. Antiangiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev 2003; 27:229-38.
3. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993; 328:1237-43.
4. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-7.
5. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-86.
6. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, Diaz C, Hernandez G, Egido J. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32:2057-64.
7. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. Nature 1999; 398:381.
8. Carlile J, Harada K, Baillie R, Macluskey M, Chisholm DM, Ogden GR, Schor SL, Schor AM. Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation. J Oral Pathol Med 2001; 30:449-57.
9. Dell'Aica I, Dona M, Sartor L, Pezzato E, Garbisa S. (-)Epigallocatechin- 3-gallate directly inhibits MT1-MMP activity, leading to accumulation of non-activated MMP-2 at the cell surface. Lab Invest 2002; 82:1685-93.
10. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 2000; 40:167-78.
11. Feng C, Ye C, Liu X, Ma H, Li M. beta4 integrin is involved in statin-induced endothelial cell death. Biochem Biophys Res Commun 2004; 323:858-64.
12. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400. Review.
13. Folkman, J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
14. Folkman J. Cancer without disease. Nature 2004.427:787.
15. Garbisa S, Biggin S, Cavallarin N, Sartor L, Benelli R, Albini A. Tumor invasion: molecular shears blunted by green tea. Nat Med 1999; 5:1216.
16. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R, Albini A. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer 2001; 91:822-32.
17. Giavazzi R, Giuliani R, Coltrini D, Bani M, Ferri C, Sennino B, et al. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res 2001; 61:309-17.
18. Hiran TS, Mazurkiewicz JE, Kreienberg P, Rice FL, LaFlamme SE. Endothelial expression of the alpha6beta4 integrin is negatively regulated during angiogenesis. J Cell Sci 2003; 116:3771-81.
19. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001; 61:2736-43.
20. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6:41-8.
21. Jimenez B, Volpert OV. Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med 2001; 78:663-72.
22. Lamy S, Gingras D, Beliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res 2002; 62:381-5.
23. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5:1418-23.
24. Jung YD, Kim MS, Shin BA, Chay KO, Ahn BW, Liu W, et al. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 2001; 84:844-50.
25. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58:409-12.
26. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6:1004-10. Erratum in: Nat Med 2001; 7:129.
27. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92:3172-7.
28. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97:1129-35.
29. Lingen MW, DiPietro LA, Solt DB, Bouck NP, Polverini PJ.The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFbeta-1 and is unaffected by ras activation. Carcinogenesis 1997; 18:329-38.
30. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 1989; 17:691-4.
31. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000; 164:820-5.
32. Miao JY, Araki S, Kaji K, Hayashi H. Integrin beta4 is involved in apoptotic signal transduction in endothelial cells. Biochem Biophys Res Commun 1997; 233:182-6.
33. Muller C, Bockhorn AG, Klusmeier S, Kiehl M, Roeder C, Kalthoff H, Koch OM. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol 1998; 12:717-23.
34. Newman A, Clutterbuck RD, Powles RL, Millar JL. Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin. Leukemia 1994; 8:2023-9.
35. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in Ape delta716 knockout mice by inhibition of cyclooxygenase 2(COX-2). Cell 1996; 87:80-9.
36. Pedersen TR, Wilhelmsen L, Færgeman D, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyörälä K, Wedel H on behalf of the Scandinavian Simvastatin Survival Study Group. A follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol lowering. The American Journal of Cardiology 2000; 86:257-262.
37. Perez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994; 199:1209-15.
38. Ravid T, Avner R, Polak-Charcon S, Faust JR, Roitelman J. Impaired regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation in lovastatin-resistant cells. J Biol Chem 1999; 274:29341-51.
39. Sandier AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 2004; 10:4258s-4262s.
40. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002; 16:2-14.
41. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99:4349-54.
42. Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ Res 2002; 90:737-44.
43. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T, Vannier JP, Soria J, Soria C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 2001; 495:159-66.
44. Volpert OV. Modulation of endothelial cell survival by an inhibitor of angiogenesis thrombospondin-1: a dynamic balance. Cancer Metastasis Rev 2000; 19:87-92.
45. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8:349-57.
46. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105:739-45.
47. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16:508-19.
48. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004; 38:1258-64.